Applied UV Declares Monthly Preferred Stock Dividend
Applied UV (NASDAQ:AUVI) has authorized a cash dividend of $0.21875 per share for holders of its 10.5% Series A Cumulative Perpetual Preferred Stock (NASDAQ:AUVIP). The dividend payment is scheduled for on or about March 15, 2022, to shareholders of record as of March 4, 2022. The company focuses on pathogen elimination technologies through UVC light, targeting healthcare and other sectors.
- Authorized cash dividend of $0.21875 per share for preferred stockholders.
- Dividend payment signifies company confidence and commitment to shareholders.
- None.
MOUNT VERNON, NY / ACCESSWIRE / February 22, 2022 / Applied UV, Inc. (NASDAQ:AUVI) ("Applied UV" or the "Company"), a pathogen elimination technology company that applies the power of narrow-range ultraviolet light ("UVC") for surface areas and catalytic bioconversion technology for air purification to destroy pathogens safely, thoroughly, and automatically, today announced its Board of Directors has authorized the cash dividend to holders of Applied UV's
Holders of the
The preferred dividend will be paid on or about March 15, 2022, to respective holders of record at the close of business on March 4, 2022.
About Applied UV
Applied UV is focused on the development and acquisition of technology that address infection control in the healthcare, hospitality, commercial and municipal markets. The Company has two wholly owned subsidiaries - SteriLumen, Inc. ("SteriLumen") and Munn Works, LLC ("Munn Works"). SteriLumen's connected platform for Data Driven Disinfection™ applies the power of ultraviolet light (UVC) to destroy pathogens safely, thoroughly, and automatically, addressing the challenge of healthcare-acquired infections ("HAIs"). Targeted for use in facilities that have high customer turnover such as hospitals, hotels, commercial facilities, and other public spaces, the Company's Lumicide™ platform uses UVC LEDs in several patented designs for infection control in and around high-traffic areas, including sinks and restrooms, killing bacteria, viruses, and other pathogens residing on hard surfaces within devices' proximity. The Company's patented in-drain disinfection device, Lumicide Drain, is the only product on the market that addresses this critical pathogen intensive location. SteriLumen's Airocide® products for air purification, developed for NASA and FDA Cleared as class II medical devices, utilize a proprietary photo-catalytic bioconversion technology that draws air into a reaction chamber that converts damaging molds, microorganisms, dangerous pathogens, destructive VOCs and biological gasses into harmless water vapor without producing ozone or other harmful byproducts. Airocide® applications include healthcare, hospitality, grocery chains, wine making facilities, commercial real estate, schools, dental offices, and homes.
For more information about Applied UV, Inc., and its subsidiaries, please visit the following websites: https://www.applieduvinc.com/; https://sterilumen.com/; https://www.airocide.comhttps://kesscience.com; https://scientificairmanagement.com and, https://munnworks.com/.
Forward-Looking Statements
The information contained herein may contain "forward‐looking statements." Forward‐looking statements reflect the current view about future events. When used in this press release, the words "anticipate," "believe," "estimate," "expect," "future," "intend," "plan," or the negative of these terms and similar expressions, as they relate to us or our management, identify forward‐looking statements. Such statements include, but are not limited to, statements contained in this press release relating to the view of management of Applied UV concerning its business strategy, future operating results and liquidity and capital resources outlook. Forward‐looking statements are based on the Company's current expectations and assumptions regarding its business, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict. The Company's actual results may differ materially from those contemplated by the forward‐looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward‐looking statements. Factors or events that could cause the Company's actual results to differ may emerge from time to time, and it is not possible for the Company to predict all of them. The Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward‐looking statements to conform these statements to actual results.
For additional Company Information:
Applied UV Inc.
Max Munn
Applied UV Interim CEO
Max.munn@sterilumen.com
CONTACT
Brett Maas, Managing Principal
Hayden IR
brett@haydenir.com
(646) 536-7331
SOURCE: Applied UV, Inc.
View source version on accesswire.com:
https://www.accesswire.com/689749/Applied-UV-Declares-Monthly-Preferred-Stock-Dividend
FAQ
What is the dividend amount for Applied UV's preferred stock?
When will the dividend for AUVI and AUVIP be paid?
Who are the shareholders eligible for the dividend?
What is the significance of the dividend for AUVI shareholders?
